This review assessed the effectiveness of hyperbaric oxygen treatment in neonates with hypoxic-ischaemic encephalopathy. It concluded that oxygen treatment may reduce mortality and neurologic sequelae, but trial reports were of poor quality and a large randomised controlled trial is needed. The review was well-conducted and these conclusions, based on the Chinese literature, seem reliable.
Data extraction
Two reviewers independently extracted the data using a predesigned form and there were no disagreements. The outcomes extracted were the total effectiveness rate (as measured by the individual studies), mean days to recovery, length of follow-up and number of losses to follow-up, numbers of deaths and long-term neurological sequelae, and adverse events. The odds ratios (OR) and 95% confidence intervals (CIs) for each study were calculated for mortality and neurological sequelae.
Methods of synthesis
How were the studies combined? Meta-analyses of mortality and neurological sequelae were conducted using fixed-effect models in the absence of statistical heterogeneity or random-effects models in the presence of statistical heterogeneity. Other results were synthesised narratively.
How were differences between studies investigated?
Statistical heterogeneity was assessed using a chi-squared test and the I-squared statistic.
Results of the review
Twenty studies (n=1,855) were included: 17 randomised trials (n=1,494) and 3 quasi-randomised trials (n=361). The numbers of patients in each trial ranged from 40 to 198.
All of the included trials were conducted in China and published in Chinese medical journals. Quality aspects were poorly reported as, although most mentioned the word 'random', none reported the method of randomisation or if allocation was concealed. Only one trial reported blinding and none gave reasons for any loss to follow-up. The only trials with intention-to-treat analyses were those with no losses to follow-up.
Hyperbaric oxygen treatment resulted in statistically significant reductions in both mortality (OR 0.26, 95% CI: 0.14, 0.46; based on 7 trials) and neurological sequelae (OR 0.41, 95% CI: 0.27, 0.61; based on 7 trials). No heterogeneity was observed for either outcome (I-squared 0%). Adverse events were reported by 8 trials, of which seven reported that there were no adverse events and one reported rentrolental fibroplasias in two neonates (one intervention and one control).
